Advances in Cancer Immunotherapy: New Insights, Novel Checkpoints
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 2302
Special Issue Editors
Interests: cancer; lung cancer; immunotherapy; immune-related adverse events
Special Issues, Collections and Topics in MDPI journals
Interests: cancer; lung cancer; head and neck cancer; immunotherapy; immune-related adverse events
Special Issues, Collections and Topics in MDPI journals
Interests: cancer; lung cancer; treatment; immunotherapy; vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The incorporation of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors into the treatment algorithm of different tumor types has revolutionized cancer care. However, only a subgroup of patients benefit from the currently approved immune therapies. The human tumor microenvironment is governed by the crosstalk between multiple immune regulatory molecules and/or pathways. Thus, in the majority of cases, the elicitation of deep and sustained antitumor responses may require more than the manipulation of a sole immune checkpoint.
This Special Issue aims to provide a comprehensive collection of review articles on the key advances in, and emerging targets for, cancer immunotherapy.
We look forward to receiving your contributions.
Dr. Konstantinos Syrigos
Dr. Ioannis Vathiotis
Dr. Andriani Charpidou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- treatment
- immunotherapy
- vaccine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
